Jubilant Life Sciences, an integrated Pharmaceuticals and Life Sciences Company, witnessed a rise in share price on Tuesday after it has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (US FDA) for Montelukast Sodium Chewable Tablets, 4 mg and 5 mg, the generic version of Singulair Chewable Tablets (of Merck), which is used for the treatment of asthma and to relieve symptoms of seasonal allergies. The total market size for Montelukast Tablets as per IMS is USD 83 million per annum.
Shares of the company are trading at Rs 169.10, up Rs 9.8, or 6.15% at the Bombay Stock Exchange (BSE) on Tuesday at 10:08 a.m.
The scrip has touched an intra-day high of Rs 175.15 and low of Rs 168.05. The total volume of shares traded at the BSE is 171,462.